secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001493152-23-039162
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Zyversa Therapeutics stockholders approve increase in authorized shares and reverse stock split authorization
--------------------------------------------------------------------------------

- Elected Class I directors Gregory G. Freitag and James Sapirstein with ~12.1M votes each.
- Ratified Ernst & Young as independent auditor for 2023 (16.5M for, 3.1M against).
- Approved increase in authorized capital stock from 111M to 251M shares (13.4M for, 6.3M against).
- Approved amendment to 2022 Omnibus Equity Incentive Plan, adding 4M shares (10.9M for).
- Authorized reverse stock split at ratio between 1:10 and 1:50, board discretion (13.3M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223039162/0001493152-23-039162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223039162/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer